These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11330269)

  • 1. Prostate cancer screening.
    Finne P; Auvinen A; Stenman UH
    Lancet; 2001 Apr; 357(9263):1201; author reply 1201-2. PubMed ID: 11330269
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer screening.
    Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
    Lancet; 2001 Apr; 357(9263):1202-3. PubMed ID: 11332426
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer screening.
    Ablin AJ
    Lancet; 2001 Apr; 357(9263):1201-2; author reply 1201-2. PubMed ID: 11332425
    [No Abstract]   [Full Text] [Related]  

  • 4. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
    Wolk A; Andersson SO; Mantzoros CS; Trichopoulos D; Adami HO
    Lancet; 2000 Dec; 356(9245):1902-3. PubMed ID: 11130391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making sense of PSA.
    Thompson IM
    Health News; 2001 Apr; 7(4):3. PubMed ID: 11303477
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) as serum markers of prostate cancer].
    Matsubara A; Nakamoto T; Usui T
    Nihon Rinsho; 2000 Jul; 58 Suppl():157-62. PubMed ID: 11022706
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate cancer screening.
    Mannello F; Gazzanelli G
    Lancet; 2001 Apr; 357(9263):1202. PubMed ID: 11379564
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate Cancer. Progress in screening, prevention holds promise.
    Harv Health Lett; 1998 Jul; 23(9):4-5. PubMed ID: 9666746
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory mechanisms in prostate cancer.
    Jefferson K; Dwivedi A; Persad R; Holly J
    Lancet; 2000 Mar; 355(9209):1100-1. PubMed ID: 10744117
    [No Abstract]   [Full Text] [Related]  

  • 12. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer.
    Smith GL; Doherty AP; Mitchell H; Hanham IW; Christmas TJ; Epstein RJ
    Lancet; 1999 Dec; 354(9195):2053-4. PubMed ID: 10636379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study.
    Borugian MJ; Spinelli JJ; Sun Z; Kolonel LN; Oakley-Girvan I; Pollak MD; Whittemore AS; Wu AH; Gallagher RP
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):252-4. PubMed ID: 18199733
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 18. A more accurate prostate test?
    Health News; 2001 Jan; 7(1):6. PubMed ID: 11198413
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.